3.79
price down icon2.07%   -0.08
after-market After Hours: 3.85 0.06 +1.58%
loading
Aldeyra Therapeutics Inc stock is traded at $3.79, with a volume of 2.54M. It is down -2.07% in the last 24 hours and up +72.27% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$3.87
Open:
$3.97
24h Volume:
2.54M
Relative Volume:
1.45
Market Cap:
$160.82M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-5.0533
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+24.26%
1M Performance:
+72.27%
6M Performance:
-23.28%
1Y Performance:
+11.47%
1-Day Range:
Value
$3.735
$3.995
1-Week Range:
Value
$2.95
$3.995
52-Week Range:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Name
Aldeyra Therapeutics Inc
Name
Phone
781-761-4904
Name
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Employee
8
Name
Twitter
@aldeyraaldx
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ALDX's Discussions on Twitter

Compare ALDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
3.79 160.82M 0 -44.80M -30.67M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-24 Upgrade Oppenheimer Perform → Outperform
Apr-02-24 Resumed H.C. Wainwright Buy
Apr-27-22 Resumed H.C. Wainwright Buy
Feb-08-21 Initiated H.C. Wainwright Buy
Dec-16-20 Initiated Berenberg Buy
Oct-30-20 Initiated Jefferies Buy
Oct-16-20 Initiated BTIG Research Buy
Sep-22-20 Initiated Alliance Global Partners Buy
May-12-20 Initiated Oppenheimer Outperform
Dec-04-18 Initiated Citigroup Buy
Sep-26-18 Reiterated Cantor Fitzgerald Overweight
Sep-13-18 Initiated Janney Buy
Jan-26-18 Initiated Seaport Global Securities Buy
Sep-26-16 Initiated H.C. Wainwright Buy
Jul-01-16 Initiated Stifel Buy
Jul-01-15 Initiated Canaccord Genuity Buy
Mar-25-15 Initiated Chardan Capital Markets Buy
Mar-20-15 Reiterated H.C. Wainwright Buy
Nov-18-14 Initiated H.C. Wainwright Buy
Jun-19-14 Initiated Aegis Capital Buy
View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits NDA for dry eye disease drug after trial success - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits NDA for dry eye disease drug after trial success By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits Reproxalap's marketing application to FDA - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application f - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra (ALDX) Resubmits Drug Application for Dry Eye Treatment to FDA | ALDX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Resubmits Reproxalap NDA to FDA - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection - Stock Titan

Jun 17, 2025
pulisher
Jun 11, 2025

Aldeyra Therapeutics Holds Annual Meeting with Key Votes - TipRanks

Jun 11, 2025
pulisher
Jun 10, 2025

Trend Tracker for (ALDX) - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 08, 2025

Two Sigma Investments LP Sells 15,349 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

161,926 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Purchased by Millennium Management LLC - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Purchases 36,160 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

BNP Paribas Financial Markets Trims Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Reduces Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Acquires Shares of 14,031 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Two Sigma Advisers LP Sells 84,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Jun 04, 2025
pulisher
May 29, 2025

Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com

May 29, 2025
pulisher
May 29, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire

May 29, 2025
pulisher
May 26, 2025

Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 26, 2025
pulisher
May 25, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World

May 25, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 24, 2025
pulisher
May 23, 2025

Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World

May 23, 2025
pulisher
May 22, 2025

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World

May 22, 2025
pulisher
May 22, 2025

Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World

May 22, 2025
pulisher
May 21, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World

May 21, 2025
pulisher
May 20, 2025

Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 20, 2025
pulisher
May 20, 2025

Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

(ALDX) Trading Report - news.stocktradersdaily.com

May 18, 2025
pulisher
May 18, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent

May 18, 2025
pulisher
May 18, 2025

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 14, 2025

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune

May 14, 2025
pulisher
May 14, 2025

Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 13, 2025
pulisher
May 12, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire

May 12, 2025
pulisher
May 11, 2025

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

May 11, 2025
pulisher
May 08, 2025

(ALDX) Trading Advice - news.stocktradersdaily.com

May 08, 2025
pulisher
May 08, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune

May 07, 2025
pulisher
May 07, 2025

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView

May 07, 2025
pulisher
May 07, 2025

Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st

May 07, 2025
pulisher
May 07, 2025

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire

May 07, 2025

Aldeyra Therapeutics Inc Stock (ALDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Machatha Stephen
Chief Development Officer
Aug 12 '24
Sale
4.74
16,041
75,975
236,771
Greenberg Bruce
See Remarks
Aug 12 '24
Sale
4.74
10,834
51,313
126,382
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Cap:     |  Volume (24h):